We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
This web publication constitutes a notice for the purposes of regulations 42ZCZS and 42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations). In accordance with regulations 42ZCZS and 42ZCZX, this notice publishes:
- Decisions made by a delegate of the Secretary pursuant to regulations 42ZCZR, 42ZCZW and 42ZCZU.
- reasons for that final decision
- date of effect of the decision.
Final decisions and reasons
We aim to provide documents in an accessible format. If you're having problems using this document, please contact medicines.scheduling@health.gov.au.
Contents
- Notice of final decisions to amend (or not amend) the current Poisons Standard
- Final decisions on proposed amendments referred to the Advisory Committee on Medicines Scheduling (ACMS #45, June 2024)
- sildenafil
- Final decisions on proposed amendments referred to the Advisory Committee on Chemicals Scheduling (ACCS #39, June 2024)
- allyl esters
- glyoxylic acid
- Final decisions on proposed amendments referred to the Advisory Committees on Medicines and Chemicals Scheduling in joint session (ACMS-ACCS #37, June 2024)
- sulfonamides
- Delegate-only decisions
- fluoride
- molidustat
- desloratidine
- Amendments to the Poison Standard in relation to New Chemical Entities (NCEs)
- Abaloparatide
- Dexrazoxane
- Efgartigimod alfa
- Elacestrant dihydrochloride
- Fedratinib
- Garadacimab
- Inebilizumab
- Marstacimab
- Momelotinib
- Palopegteriparatide
- Rozanolixizumab
- Sodium citrate dihydrate
- Zolbetuximab
- Cipaglucosidase alfa